Overview Dividends

(DOC) Healthpeak Properties - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US42250P1030

Properties, Care, Facilities, Research, Outpatient

DOC EPS (Earnings per Share)

EPS Growth (3Y CAGR): -75.41%
EPS Trend (3Y Correlation): -31.0%

DOC Revenue

Revenue Growth (3Y CAGR): 25.23%
Revenue Trend (3Y Correlation): 90.9%

Description: DOC Healthpeak Properties October 31, 2025

Healthpeak Properties, Inc. (NYSE: DOC) is a fully integrated REIT and S&P 500 constituent that owns, operates, and develops premium real-estate assets dedicated to healthcare discovery and delivery. Its portfolio is concentrated in life-science labs, medical office buildings, and senior housing, positioning the company within the GICS sub-industry “Health Care REITs.”

Key quantitative highlights (as of the latest FY 2024 filing) include an occupancy rate of roughly 96 % across its life-science and medical-office assets, a FY 2024 adjusted FFO of about $1.12 billion (≈ 6.5 % year-over-year growth), and a dividend yield near 5.8 % paid quarterly. The REIT’s performance is closely tied to macro drivers such as the aging U.S. population (projected to reach 21 % of the total by 2030), sustained federal funding for medical research, and the prevailing interest-rate environment, which influences both borrowing costs and the relative attractiveness of dividend-yielding REITs versus fixed-income alternatives.

If you want a deeper, data-rich analysis of DOC’s valuation metrics and scenario modeling, a quick look at ValueRay’s platform can provide the granular tools needed for further research.

DOC Stock Overview

Market Cap in USD	12,189m
Sub-Industry	Health Care REITs
IPO / Inception	1987-11-05

DOC Stock Ratings

Growth Rating	-42.8%
Fundamental	57.9%
Dividend Rating	28.4%
Return 12m vs S&P 500	-26.8%
Analyst Rating	4.25 of 5

DOC Dividends

Dividend Yield 12m	6.86%
Yield on Cost 5y	6.14%
Annual Growth 5y	-12.14%
Payout Consistency	97.1%
Payout Ratio	504.2%

DOC Growth Ratios

Growth Correlation 3m	48.6%
Growth Correlation 12m	-61.2%
Growth Correlation 5y	-64.6%
CAGR 5y	-4.18%
CAGR/Max DD 3y (Calmar Ratio)	-0.10
CAGR/Mean DD 3y (Pain Ratio)	-0.21
Sharpe Ratio 12m	-0.71
Alpha	-35.44
Beta	1.098
Volatility	28.51%
Current Volume	6930.6k
Average Volume 20d	9167.3k
Stop Loss	17.2 (-3.5%)
Signal	-0.56

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-38.2m TTM) > 0 and > 6% of Revenue (6% = 184.1m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA -0.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -6.70% (prev -23.75%; Δ 17.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 926.4m > Net Income -38.2m (YES >=105%, WARN >=100%)

Net Debt (9.43b) to EBITDA (1.56b) ratio: 6.04 <= 3.0 (WARN <= 3.5)

Current Ratio 0.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (696.4m) change vs 12m ago -0.54% (target <= -2.0% for YES)

Gross Margin 63.56% (prev 60.01%; Δ 3.55pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 15.52% (prev 12.80%; Δ 2.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.66 (EBITDA TTM 1.56b / Interest Expense TTM 295.0m) >= 6 (WARN >= 3)

Altman Z'' -1.36

(A) -0.01 = (Total Current Assets 764.5m - Total Current Liabilities 970.1m) / Total Assets 19.58b

(B) -0.30 = Retained Earnings (Balance) -5.85b / Total Assets 19.58b

(D) -0.46 = Book Value of Equity -5.17b / Total Liabilities 11.32b

Total Rating: -1.36 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 57.85

1. Piotroski 2.50pt = -2.50

2. FCF Yield 4.27% = 2.14

3. FCF Margin 30.19% = 7.50

4. Debt/Equity 1.26 = 1.75

5. Debt/Ebitda 6.04 = -2.50

6. ROIC - WACC (= -2.98)% = -3.73

7. RoE -0.48% = -0.08

8. Rev. Trend 90.85% = 6.81

9. EPS Trend -31.03% = -1.55

What is the price of DOC shares?

As of November 10, 2025, the stock is trading at USD 17.82 with a total of 6,930,590 shares traded.
Over the past week, the price has changed by -0.72%, over one month by -6.38%, over three months by +6.87% and over the past year by -16.54%.

Is Healthpeak Properties a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Healthpeak Properties is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 57.85 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DOC is around 17.62 USD . This means that DOC is currently overvalued and has a potential downside of -1.12%.

Is DOC a buy, sell or hold?

Healthpeak Properties has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy DOC.

Strong Buy: 10
Buy: 5
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DOC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	21	18%
Analysts Target Price	21	18%
ValueRay Target Price	19.1	7.4%

DOC Fundamental Data Overview November 06, 2025

Market Cap USD = 12.19b (12.19b USD * 1.0 USD.USD)
P/E Forward = 80.0
P/S = 4.3517
P/B = 1.6812
P/EG = 4.0809
Beta = 1.098
Revenue TTM = 3.07b USD
EBIT TTM = 490.8m USD
EBITDA TTM = 1.56b USD
Long Term Debt = 8.57b USD (from longTermDebt, last fiscal year)
Short Term Debt = 171.5m USD (from shortTermDebt, last fiscal year)
Debt = 9.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.43b USD (from netDebt column, last quarter)
Enterprise Value = 21.69b USD (12.19b + Debt 9.59b - CCE 91.0m)
Interest Coverage Ratio = 1.66 (Ebit TTM 490.8m / Interest Expense TTM 295.0m)
FCF Yield = 4.27% (FCF TTM 926.4m / Enterprise Value 21.69b)
FCF Margin = 30.19% (FCF TTM 926.4m / Revenue TTM 3.07b)
Net Margin = -1.25% (Net Income TTM -38.2m / Revenue TTM 3.07b)
Gross Margin = 63.56% ((Revenue TTM 3.07b - Cost of Revenue TTM 1.12b) / Revenue TTM)
Gross Margin QoQ = 70.02% (prev 60.22%)
Tobins Q-Ratio = 1.11 (Enterprise Value 21.69b / Total Assets 19.58b)
Interest Expense / Debt = 0.80% (Interest Expense 76.8m / Debt 9.59b)
Taxrate = 171.3% (out of range, set to none) (264.0m / 154.1m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 0.79 (Total Current Assets 764.5m / Total Current Liabilities 970.1m)
Debt / Equity = 1.26 (Debt 9.59b / totalStockholderEquity, last quarter 7.60b)
Debt / EBITDA = 6.04 (Net Debt 9.43b / EBITDA 1.56b)
Debt / FCF = 10.18 (Net Debt 9.43b / FCF TTM 926.4m)
Total Stockholder Equity = 8.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.20% (Net Income -38.2m / Total Assets 19.58b)
RoE = -0.48% (Net Income TTM -38.2m / Total Stockholder Equity 8.03b)
RoCE = 2.96% (EBIT 490.8m / Capital Employed (Equity 8.03b + L.T.Debt 8.57b))
RoIC = 2.65% (EBIT 490.8m / (Assets 19.58b - Curr.Liab 970.1m - Cash 91.0m))
WACC = 5.63% (E(12.19b)/V(21.78b) * Re(10.06%) + (debt cost/tax rate unavailable))
Discount Rate = 10.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 12.79%
[DCF Debug] Terminal Value 73.06% ; FCFE base≈963.2m ; Y1≈1.07b ; Y5≈1.40b
Fair Price DCF = 24.89 (DCF Value 17.30b / Shares Outstanding 694.9m; 5y FCF grow 12.72% → 3.0% )
EPS Correlation: -31.03 | EPS CAGR: -75.41% | SUE: -4.0 | # QB: 0
Revenue Correlation: 90.85 | Revenue CAGR: 25.23% | SUE: 4.0 | # QB: 1

Additional Sources for DOC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle